Short Communication

Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations

Sareh Manouchehri

Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Stuart Ibsen

Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Jennifer Wright

Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Laura Rassenti

Department of Nanoengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Emanuela M Ghia

Department of Nanoengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

George F Widhopf

Department of Nanoengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Thomas J Kipps

Department of Nanoengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Michael J Heller

*Author for correspondence:

E-mail Address: mheller@ucsd.edu

Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA

Search for more papers by this author

Published Online:5 May 2016https://doi.org/10.2217/ijh-2015-0009

View article

Abstract

Aim: Circulating cell free (ccf) DNA contains information about mutations affecting chronic lymphocytic leukemia (CLL). The complexity of isolating DNA from plasma inhibits the development of point-of-care diagnostics. Here, we introduce an electrokinetic method that enables rapid recovery of DNA from plasma. Materials & methods: ccf-DNA was isolated from 25 µl of CLL plasma using dielectrophoresis. The DNA was used for PCR amplification, sequencing and analysis. Results: The ccf-DNA collected from plasma of 5 CLL patients revealed identical mutations to those previously identified by extracting DNA from CLL cells from the same patients. Conclusion: Rapid dielectrophoresis isolation of ccf-DNA directly from plasma provides sufficient amounts of DNA to use for identification of point mutations in genes associated with CLL progression.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 American Cancer Society. www.cancer.org/.Google Scholar
2 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9–29 (2014).Crossref, Medline, Google Scholar
3 Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: current status and future perspectives. Cancer Lett. 352(1), 4–14 (2014).Crossref, Medline, CAS, Google Scholar
4 Nabhan C, Raca G, Wang YL. Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol. 1(7), 965–974 (2015).Crossref, Medline, Google Scholar
5 Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood 111(12), 5446–5456 (2008). • This article shows the clinical methods used for extracting and processing DNA from chronic lymphocytic leukemia cell samples as well as the common types of genomic mutations found.Crossref, Medline, CAS, Google Scholar
6 Edelmann J, Holzmann K, Miller F et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120(24), 4783–4794 (2012).Crossref, Medline, CAS, Google Scholar
7 Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukemia. Nat. Rev. Cancer 10(1), 37–50 (2010).Crossref, Medline, CAS, Google Scholar
8 Gonzalez D, Martinez P, Wade R et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J. Clin. Oncol. 29(16), 2223–2229 (2011).Crossref, Medline, Google Scholar
9 Fabbri G, Rasi S, Rossi D et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208(7), 1389–1401 (2011).Crossref, Medline, CAS, Google Scholar
10 Oscier DG, Rose-Zerilli MJJ, Winkelmann N et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 121(3), 468–475 (2013).Crossref, Medline, CAS, Google Scholar
11 Rossi D, Rasi S, Spina V et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121(8), 1403–1412 (2013).Crossref, Medline, CAS, Google Scholar
12 Foà R, Del Giudice I, Guarini A, Rossi D, Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 98(5), 675–685 (2013).Crossref, Medline, CAS, Google Scholar
13 Roschewski M, Dunleavy K, Pittaluga S et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 16(5), 541–549 (2015).Crossref, Medline, Google Scholar
14 Forshew T, Murtaza M, Parkinson C et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl Med. 4(136), 136ra68–136ra68 (2012).Crossref, Medline, Google Scholar
15 Leary RJ, Sausen M, Kinde I et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl Med. 4(162), 162ra154 (2012).Crossref, Medline, Google Scholar
16 Morgan SR, Whiteley J, Donald E et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin. Med. Insights Pathol. 5, 15–22 (2012).Crossref, Medline, CAS, Google Scholar
17 Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32(6), 579–586 (2014). • This article was selected as a reference as it talks about the correlation between the circulating cell free-(ccf) DNA and cancer dynamics, and it concludes the mutations found in ccf-DNA are specific to an individual's cancer.Crossref, Medline, Google Scholar
18 Jin D, Xie S, Mo Z, Liang Y, Guo YM. Circulating DNA-important biomarker of cancer. J. Mol. Biomarkers Diagn. S2, 009 (2012).Google Scholar
19 Kohler C, Barekati Z, Radpour R, Zhong XY. Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res. 31(8), 2623–2628 (2011).Medline, CAS, Google Scholar
20 Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11(6), 426–437 (2011).Crossref, Medline, CAS, Google Scholar
21 Sonnenberg A, Marciniak JY, Skowronski EA et al. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis 35(12–13), 1828–1836 (2014). •• This article shows the comparison between the ccf-DNA recovered from plasma of chronic lymphocytic leukemia patients by dielectrophoresis and the gold standard Qiagen kit. Comparisons were made for the processing time and the genetic analysis between the two methods. i.e., mutations in IGVH gene.Crossref, Medline, CAS, Google Scholar
22 Sonnenberg A, Marciniak Jennifer Y, Rassenti L et al. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin. Chem. 60(3), 500–509 (2014).Crossref, Medline, CAS, Google Scholar
23 Sonnenberg A, Marciniak JY, Krishnan R, Heller M. Dielectrophoretic isolation of DNA and nanoparticles from blood. Electrophoresis 33(16), 2482–2490 (2012). •• This article demonstrates the use of dielectrophoresis technology to separate DNA from blood.Crossref, Medline, CAS, Google Scholar
24 Sonnenberg A, Marciniak JY, McCanna J et al. Dielectrophoretic isolation and detection of cfcDNA nanoparticulate biomarkers and virus from blood. Electrophoresis 34(7), 1076–1084 (2013).Crossref, Medline, CAS, Google Scholar
25 Qian C, Huang H, Chen L et al. Dielectrophoresis for bioparticle manipulation. Int. J. Mol. Sci. 15(10), 18281–18309 (2014).Crossref, Medline, CAS, Google Scholar
26 McCanna JP, Sonnenberg A, Heller MJ. Low level epifluorescent detection of nanoparticles and DNA on dielectrophoretic microarrays. J. Biophotonics 7(11–12), 863–873 (2014).Crossref, Medline, CAS, Google Scholar
27 Rassenti LZ, Jain S, Keating MJ et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112, 1923–1930 (2008).Crossref, Medline, CAS, Google Scholar
28 Schwaederlé M, Ghia E, Rassenti LZ et al. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia 27(5), 1214–1217 (2013).Crossref, Medline, CAS, Google Scholar

Vol. 5, No. 1

Metrics

Downloaded 42 times

History

Published online 5 May 2016

Published in print May 2016

Information

Keywords

Acknowledgements

The authors wish to thank R Krishnan, D Charlot and JP Hinestrosa at Biological Dynamics for their cooperation and for providing the equipment for this study. The authors also thank A Wright for his help with MATLAB image processing.

Financial & competing interests disclosure

The DEP technology used in the study was the result of original research carried out by the MJ Heller laboratory at the UCSD Moores Cancer Center under NIH NCI NanoTumor Center Grant (U54-CA119335). The work was also funded in part by NIH SBIR grant 1R43CA183414-01. Other than MJ Heller who is on the Scientific Advisory Board of Biological Dynamics (La Jolla, CA), no other authors have any relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download